Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under ...

The Oscar-nominated actress talks about playing the activist whose 1990s lawsuit demanding equal pay with her male colleagues went all the way to the Supreme Court, and how her own mother inspired her ...

While ILCG offers diversified growth exposure, its elevated volatility and lagging performance against top growth funds ...

Business leaders from major Hoosier companies say they are trying to navigate the uncertain trade environment created by ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...